Document: Questions and answers on the outcome of assessment on use of Revolade in treatment of severe aplastic anaemia in children-2025/8/25

Document: Information on the Member States requirement for the nomination of a pharmacovigilance (PhV) contact person at national level-2025/10/1

关于公开征求《重组表达单克隆抗体类生物制品制造及检定规程撰写指南（征求意见稿）》意见的通知-2025/11/10

Document: Agenda of the CHMP meeting 8-11 December 2025-2025/12/8

Document: Union list of critical medicines - version 2.1 (revision 1)-2026/1/19

Document: Agenda of the CAT meeting 18-20 February 2026-2026/2/18

Document: QRD Appendix II - Medical Dictionary for Regulatory Activities terminology to be used in section 4.8 'undesirable effects' of the summary of product characteristics-2026/3/25

Page: PRAC recommendations on safety signals-2026/5/4

Document: IRIS guide to registration and RPIs-2026/6/15

Document: Minutes – Ad hoc Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 12 June 2026-2026/7/24